Semaglutide is a GLP-1 receptor agonist prescribed for weight management and blood sugar control. NextGen PGx testing reports genetic variants studied for their possible relevance to medication-processing pathways relevant to this medication class.
Your NextGen PGx report reviews genetic variants associated with relevant metabolic pathways and presents them with clear evidence-level context — never as a guarantee of outcome.
Bring your NextGen PGx report to your next appointment. Your prescriber can weigh the genetic information alongside your health history, current medications, and treatment goals.
Order your NextGen PGx PGx test today and get a unique patient ID in minutes.
Semaglutide is marketed under brand names including Ozempic® and Wegovy®, registered trademarks of Novo Nordisk. NextGen PGx is not affiliated with, sponsored by, or endorsed by Novo Nordisk.